Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting–based retrospective cohort study
Yi Xu, Shuting Zhang, Liying Wang, Yang Deng, Nan Hu · 2026
Read Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting–based retrospective cohort study by Yi Xu, Shuting Zhang, Liying Wang, Yang Deng, Nan Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551692.txt.
Description
Yi Xu, Shuting Zhang, Liying Wang, Yang Deng, and Nan Hu published a 2026 study of two last-resort drugs in very ill patients. The patients had infections that resist standard drugs. The drugs, colistin sulfate and polymyxin B, are close kin. The team reviewed ICU cases from 2023 and 2024. They weighted the groups so the comparison was fair.
Eighty-five patients got colistin and seventy-eight got polymyxin B. Cure rates, germ clearance, and death rates did not differ after weighting. Severe kidney harm was much more common with polymyxin B. The gap was sharpest in one germ subgroup. Blood drug levels did not split the outcome groups. The team urges close kidney checks keyed to drug choice.
Catalog record
| CREATOR | Yi Xu, Shuting Zhang, Liying Wang, Yang Deng, Nan Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49622 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |